ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1746

Increased CD39+FoxP3+CD4+ Regulatory T Cells in Early Rheumatoid Arthritis Provide a Slot for Prompt Initiation of Methotrexate and Serve as Early Biomarkers of Clinical Response

María-Eugenia Miranda-Carús1, Alejandro Villalba1, Laura Nuño1, Marta Benito-Miguel2, Irene Monjo1, Marta Novella-Navarro1, Diana Peiteado1, Sara Garcia-Carazo1 and Alejandro Balsa3, 1Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, 2Universidad Nebrija, Physiology, Madrid, Spain, 3Hospital La Paz Institute for Health Research, Madrid, Spain

Meeting: ACR Convergence 2022

Keywords: Biomarkers, rheumatoid arthritis, T Cell, Treg cells

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: FoxP3+ regulatory CD4+ T cells (Tregs) are key to the homeostasis of the immune system. Stressed cells at inflammatory foci release adenine nucleotides to the extracellular space that can act as enhancers of inflammation but are rapidly hydrolysed by the sequential action of ectonucleotidases CD39 and CD73 rendering the antiinflammatory agent adenosine. CD39, the rate-limiting enzyme in this cascade, is highly expressed by a subset of human FoxP3+Tregs (Treg39+). Methotrexate (MTX), the first line of treatment in Rheumatoid Arthritis (RA), inhibits AICAR transformylase which results in an enhanced release of extracellular adenine nucleotides to be metabolized by Treg39+ cells; hence MTX may cooperate with Treg39+ cells in the control of inflammation.

Methods: Peripheral blood was obtained from 72 DMARD- and steroid- naïve ERA patients with a disease duration < 24 weeks and 72 age and gender-matched healthy controls (HC). 33 ERA patients donated blood again 12 months after initiating MTX (ERA-R). The frequency of Treg and Treg cell subsets was assessed by flow cytometry. CD4+CD25+CD127- (total T reg), CD4+CD27+CD127-CD39+ Treg (Treg39+) and CD4+CD25-CD39- responder T (Tresp39-) cells were isolated by sorting. The suppressor potency of Tregs was determined in cocultures of isolated Tregs with Tresp. Proliferation was determined by CFSE dilution; cytokine secretion was measured by ELISA of culture supernatants. Disease activity was assessed using the DAS28-ESR score. Low disease activity (LDA) was defined as a DAS28 ≤3.2.

Results: ERA patients demonstrated a superior frequency of circulating Tregs containing increased proportions of Treg39+ cells. Total ERA Tregs were more potent than HC Tregs and MTX further heightened their potency, with greater amplification in ERA vs HC; differences were reduced by adenosine pathway blockade. The potency of isolated Treg39+ and its enhancement by MTX were comparable for ERA and HC suggesting that the differences seen with total Tregs are due to the increased ERA Treg39+ frequency. Basal Treg39+ proportions > 39.3 (p75 of HC) associated with a good 12 month EULAR response [RR 13.4 (2.9-75.6)]. At 12 months, the ERA Treg39+ frequency had decreased to HC levels but its association with the clinical response remained: the cTreg39+ cell frequency observed at 12 months was still significantly higher in those patients who had achieved LDA. This suggests that Treg cell expression of CD39 is upregulated during the initial stages of ERA as a negative feedback mechanism of inflammation.

Conclusion: MTX cooperates with Treg39+ cells and the basal Treg39+ frequency is a predictor of response. Increased circulating Treg39+ cells in untreated ERA would further facilitate the action of MTX thereby providing a slot for prompt MTX initiation.


Disclosures: M. Miranda-Carús, Gebro-Pharma, Bristol-Myers Squibb(BMS); A. Villalba, None; L. Nuño, None; M. Benito-Miguel, None; I. Monjo, None; M. Novella-Navarro, None; D. Peiteado, None; S. Garcia-Carazo, None; A. Balsa, Bristol-Myers Squibb(BMS), Gebro-Pharma, Novartis, Roche, UCB, Pfizer, AbbVie/Abbott, Galapagos, Gilead, Sandoz, Lilly, Nordic.

To cite this abstract in AMA style:

Miranda-Carús M, Villalba A, Nuño L, Benito-Miguel M, Monjo I, Novella-Navarro M, Peiteado D, Garcia-Carazo S, Balsa A. Increased CD39+FoxP3+CD4+ Regulatory T Cells in Early Rheumatoid Arthritis Provide a Slot for Prompt Initiation of Methotrexate and Serve as Early Biomarkers of Clinical Response [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/increased-cd39foxp3cd4-regulatory-t-cells-in-early-rheumatoid-arthritis-provide-a-slot-for-prompt-initiation-of-methotrexate-and-serve-as-early-biomarkers-of-clinical-response/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-cd39foxp3cd4-regulatory-t-cells-in-early-rheumatoid-arthritis-provide-a-slot-for-prompt-initiation-of-methotrexate-and-serve-as-early-biomarkers-of-clinical-response/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology